SEC 13F Intelligence

Dillon & Associates Inc / ABT

Dillon & Associates Inc’s Abbott Laboratories Position

Does Dillon & Associates Inc own Abbott Laboratories (ABT)? Yes231.3K shares worth $24M (+3.28% of its 13F portfolio) as of Q1 2026, up from 226.4K shares the prior filed quarter.

Position Value
$24M
Q1 2026
Shares
231.3K
% of Portfolio
+3.28%
Quarters Held
29
currently held

Position History ABT

Reported value by quarter
Q1 ’19: $17MQ1 ’19Q2 ’19: $18MQ3 ’19: $18MQ4 ’19: $18MQ1 ’20: $17MQ1 ’20Q2 ’20: $20MQ3 ’20: $23MQ4 ’20: $23MQ1 ’21: $25MQ1 ’21Q2 ’21: $24MQ3 ’21: $25MQ4 ’21: $29MQ1 ’22: $24MQ1 ’22Q2 ’22: $22MQ3 ’22: $20MQ4 ’22: $23MQ1 ’23: $21MQ1 ’23Q2 ’23: $21MQ3 ’23: $19MQ4 ’23: $21MQ1 ’24: $22MQ1 ’24Q2 ’24: $21MQ3 ’24: $24MQ4 ’24: $24MQ1 ’25: $29MQ1 ’25Q2 ’25: $30MQ3 ’25: $30MQ4 ’25: $28MQ1 ’26: $24MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026231.3K$24M+3.28%
Q4 2025226.4K$28M+3.65%
Q3 2025222.2K$30M+3.83%
Q2 2025218.7K$30M+4.04%
Q1 2025214.6K$29M+4.24%
Q4 2024213.0K$24M+3.34%
Q3 2024210.3K$24M+3.37%
Q2 2024206.0K$21M+3.11%
Q1 2024192.1K$22M+3.44%
Q4 2023192.4K$21M+3.84%
Q3 2023196.5K$19M+3.67%
Q2 2023196.5K$21M+3.94%
Q1 2023203.0K$21M+4.07%
Q4 2022205.7K$23M+4.89%
Q3 2022206.2K$20M+4.64%
Q2 2022205.8K$22M+5.06%
Q1 2022205.9K$24M+4.61%
Q4 2021208.8K$29M+5.13%
Q3 2021208.7K$25M+4.72%
Q2 2021208.1K$24M+4.73%
Q1 2021208.6K$25M+5.35%
Q4 2020211.2K$23M+5.00%
Q3 2020214.1K$23M+5.63%
Q2 2020215.1K$20M+5.30%
Q1 2020215.6K$17M+5.73%
Q4 2019211.5K$18M+5.15%
Q3 2019211.0K$18M+5.39%
Q2 2019211.0K$18M+5.48%
Q1 2019208.6K$17M+5.42%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Dillon & Associates Inc’s full portfolio or all institutional holders of ABT.